Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Clinical trial NCT06237296 · COMPLETED

Trial details

NCT number: NCT06237296
Sponsor: Sanofi Pasteur, a Sanofi Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Respiratory Syncytial Virus Infection Healthy Volunteers Metapneumovirus Infection

Start date: 2024-01-23
Primary completion: 2025-02-11
Enrollment: 558

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.